Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx: A Very Good Start For Vyvgart
07:33am, Wednesday, 25'th May 2022
argenx beat Q1 2022 revenue estimates thanks to a strong launch of Vyvgart in generalized myasthenia gravis. The early patient numbers look good compared to the launch of Soliris four years ago.
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
07:21pm, Tuesday, 24'th May 2022 Benzinga
SVB Securities initiated coverage on Argenx SE (NASDAQ: ARGX) with an Outperform rating and a $404 price target.
Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that se
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
01:35pm, Thursday, 19'th May 2022 Zacks Investment Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
11:00am, Thursday, 19'th May 2022 GlobeNewswire Inc.
May 19, 2022
argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
02:38pm, Wednesday, 18'th May 2022
Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock's expected coming price range lim
argenx announces results of Annual General Meeting of Shareholders
09:30pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
May 10, 2022
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript
07:38pm, Saturday, 07'th May 2022
argenx SE (NASDAQ:ARGX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief
argenx SE (ARGX) Q1 2022 Earnings Call Transcript
12:30pm, Friday, 06'th May 2022 The Motley Fool
ARGX earnings call for the period ending March 31, 2022.
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
11:11am, Thursday, 05'th May 2022
Argenx SE's (NASDAQ: ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 a
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
05:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
05:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
May 5, 2022
argenx to Present at BofA Securities 2022 Healthcare Conference
05:00am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
May 4, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announce
argenx to Present at BofA Securities 2022 Healthcare Conference
01:00am, Wednesday, 04'th May 2022
May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announ
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
02:04pm, Tuesday, 03'rd May 2022 Benzinga
Upgrades
For SVB Financial Group (NASDAQ:SIVB), Oppenheimer upgraded the previous rating of Perform to Outperform. For the first quarter, SVB Finl Gr had an EPS of $7.92, compared to year-ago quarter
